Serum neuropeptide Y in accident survivors with depression or posttraumatic stress disorder

Neuroscience Research

Volumn 83, Issue , 2014, Pages 8-12

  Nishi, Daisuke ^a,b,c   Hashimoto, Kenji ^d   Noguchi, Hiroko ^b,c   Matsuoka, Yutaka ^a,b,c  

^a NATIONAL HOSPITAL ORGANIZATION DISASTER MEDICAL CENTER   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

Depression; Neuropeptide Y; PTSD; Resilience

Indexed keywords

NEUROPEPTIDE Y;

ACCIDENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; POSTTRAUMATIC STRESS DISORDER; QUESTIONNAIRE; SELF REPORT; SURVIVOR; ADOLESCENT; AGED; BLOOD; COPING BEHAVIOR; ENZYME IMMUNOASSAY; MIDDLE AGED; PSYCHOLOGY; YOUNG ADULT;

ACCIDENTS; ADOLESCENT; ADULT; AGED; DEPRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEUROPEPTIDE Y; RESILIENCE, PSYCHOLOGICAL; STRESS DISORDERS, POST-TRAUMATIC; SURVIVORS; YOUNG ADULT;

EID: 84907985673     PISSN: 01680102     EISSN: 18728111     Source Type: Journal    
DOI: 10.1016/j.neures.2014.03.009     Document Type: Article

References (42)

1. Antonijevic I.A., Murck H., Bohlhalter S., Frieboes R.M., Holsboer F., Steiger A. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 2000, 39:1474-1481.
2. Association A.P. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC, London, England. Fourth Edition, Text Revision; DSM-IV-TR.
3. Asukai N., Kato H., Kawamura N., Kim Y., Yamamoto K., Kishimoto J., Miyake Y., Nishizono-Maher A. Reliability and validity of the Japanese-language version of the impact of event scale-revised (IES-R-J): four studies of different traumatic events. J. Nerv. Ment. Dis. 2002, 190:175-182.
4. Baker D.G., Bertram T.M., Patel P.M., Barkauskas D.A., Clopton P., Patel S., Geracioti T.D., Haji J.R., O'Connor U., Nievergelt D.T., Hauger C.M.R.L. Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology 2013, 38:2378-2382.
5. Baker S.P., O'Neill B. The injury severity score: an update. J. Trauma 1976, 16:882-885.
6. Bannon A.W., Seda J., Carmouche M., Francis J.M., Norman M.H., Karbon B., Mccaleb M.L. Behavioral characterization of neuropeptide Y knockout mice. Brain Res. 2000, 868:79-87.
7. Dumont Y., Jacques D., Bouchard P., Quirion R. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol. 1998, 402:372-384.
8. Fendt M., Burki H., Imobersteg S., Lingenhohl K., Mcallister K.H., Orain D., Uzunov D.P., Chaperon F. Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology 2009, 206:291-301.
9. Folstein M.F., Folstein S.E., Mchugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
10. Gjerris A., Widerlov E., Werdelin L., Ekman R. Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls. J. Psychiatry Neurosci. 1992, 17:23-27.
11. Gutman A.R., Yang Y., Ressler K.J., Davis M. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J. Neurosci. 2008, 28:12682-12690.
12. Hashimoto H., Onishi H., Koide S., Kai T., Yamagami S. Plasma neuropeptide Y in patients with major depressive disorder. Neurosci. Lett. 1996, 216:57-60.
13. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
14. Heilig M., Mcleod S., Brot M., Heinrichs S.C., Menzaghi F., Koob G.F., Britton K.T. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993, 8:357-363.
15. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 1989, 98:524-529.
16. Karl T., Chesworth R., Duffy L., Herzog H. Acoustic startle response and sensorimotor gating in a genetic mouse model for the Y1 receptor. Neuropeptides 2010, 44:233-239.
17. Karl T., Chesworth R., Duffy L., Herzog H. Schizophrenia-relevant behaviours in a genetic mouse model for Y2 deficiency. Behav. Brain Res. 2010, 207:434-440.
18. Karlsson R.M., Holmes A., Heilig M., Crawley J.N. Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice. Pharmacol. Biochem. Behav. 2005, 80:427-436.
19. Kugaya A., Akechi T., Okuyama T., Okamura H., Uchitomi Y. Screening for psychological distress in Japanese cancer patients. Jpn. J. Clin. Oncol. 1998, 28:333-338.
20. Matsuoka Y., Nishi D., Nakajima S., Yonemoto N., Hashimoto K., Noguchi H., Homma M., Otomo Y., Kim Y. The Tachikawa cohort of motor vehicle accident study investigating psychological distress: design, methods and cohort profiles. Soc. Psychiatry Psychiatr. Epidemiol. 2009, 44:333-340.
21. Morales-Medina J.C., Dumont Y., Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Res. 2010, 1314:194-205.
22. Morgan C.A., Rasmusson A.M., Wang S., Hoyt G., Hauger R.L., Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol. Psychiatry 2002, 52:136-142.
23. Morgan C.A., Rasmusson A.M., Winters B., Hauger R.L., Morgan J., Hazlett G., Southwick S. Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels. Biol. Psychiatry 2003, 54:1087-1091.
24. Mori E., Mitani Y., Yamadori A. Usefulness of a Japanese version of the Mini-Mental State Test in neurological patients. Shinkeishinrigaku 1985, 1:82-90. (in Japanese).
25. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., Mathe A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J Neuropsychopharmacol. 2005, 8:403-410.
26. Nishi D., Matsuoka Y., Nakajima S., Noguchi H., Kim Y., Kanba S., Schnyder U. Are patients after severe injury who drop out of a longitudinal study at high risk of mental disorder?. Compr. Psychiatry 2008, 49:393-398.
27. Otsubo T., Tanaka K., Koda R., Shinoda J., Sano N., Tanaka S., Aoyama H., Mimura M., Kamijima K. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin. Neurosci. 2005, 59:517-526.
28. Painsipp E., Wultsch T., Edelsbrunner M.E., Tasan R.O., Singewald N., Herzog H., Holzer P. Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice. Genes Brain Behav. 2008, 7:532-542.
29. Parker G., Manicavasagar V. Our model of non-melancholic depression. Modelling and Managing the Depressive Disorders: A Clinical Guide 2005, Cambridge Universtiy Press, New York. G. Parker, V. Manicavasagar (Eds.).
30. Rasmusson A.M., Hauger R.L., Morgan C.A., Bremner J.D., Charney D.S., Southwick S.M. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol. Psychiatry 2000, 47:526-539.
31. Redrobe J.P., Dumont Y., Fournier A., Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
32. Sah R., Ekhator N.N., Strawn J.R., Sallee F.R., Baker D.G., Horn P.S., Geracioti T.D.J.R. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol. Psychiatry 2009, 66:705-707.
33. Sah R., Geracioti T.D. Neuropeptide Y and posttraumatic stress disorder. Mol. Psychiatry 2013, 18:646-655.
34. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.
35. Sorensen G., Lindberg C., Wortwein G., Bolwig T.G., Woldbye D.P. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res. 2004, 77:723-729.
36. Southwick S.M., Charney D.S. The science of resilience: implications for the prevention and treatment of depression. Science 2012, 338:79-82.
37. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
38. Weiss D.S. The Impact of Event Scale-Revised 2004, Guilford Press, New York.
39. Weiss D.S., Marmar C.R. The Impact of Event Scale-Revised 1997, Guilford Press, New York.
40. Westrin A., Ekman R., Traskman-Bendz L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur. Neuropsychopharmacol. 1999, 9:205-211.
41. Yehuda R., Brand S., Yang R.K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry 2006, 59:660-663.
42. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.